Related Experiment Video

Updated: Aug 15, 2026

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

Current and future therapeutic approaches in idiopathic pulmonary fibrosis

D Bouros1, K M Antoniou

  • 1Department of Pneumonology, Medical School, Democritus University of Thrace, Alexandroupolis, and Department of Thoracic Medicine, University Hospital of Heraklion, Crete, Greece. bouros@med.duth.gr

The European Respiratory Journal
|October 6, 2005
PubMed

Insights

Currently, no effective treatments exist for idiopathic pulmonary fibrosis (IPF). This review highlights the lack of evidence for current therapies and the ongoing investigation into novel antifibrotic and immunoregulatory drugs for IPF.

Area of Science:

  • Pulmonology
  • Medical Research
  • Clinical Trials

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with no effective treatments.
  • Current management often relies on corticosteroids and other immunosuppressants, but evidence is limited.

Purpose of the Study:

  • To systematically review current and novel therapies for IPF, focusing on controlled trials.
  • To assess the evidence base for existing and emerging IPF treatments.

Main Methods:

  • Systematic review of randomized controlled trials and meta-analyses of IPF treatments.
  • Inclusion of English-language studies on adult IPF patients, assessing drug monotherapy and combination therapies.
  • Independent quality assessment of included studies.

Main Results:

  • A significant lack of high-quality studies evaluating the effectiveness of commonly used drugs like corticosteroids and immunosuppressants.
  • Oral corticosteroids are standard, with other agents like azathioprine, cyclophosphamide, and colchicine also used.
  • Numerous clinical trials are investigating novel antifibrotic, anticytokine, and immunoregulatory drugs.

Conclusions:

  • There are currently no evidence-based therapies proven effective for idiopathic pulmonary fibrosis.
  • Further rigorous controlled studies are essential to establish effective clinical practices for IPF management.

More Related Videos

Refined Murine Model of Idiopathic Pulmonary Fibrosis07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...